Please use this identifier to cite or link to this item: https://doi.org/10.1371/journal.pone.0210996
DC FieldValue
dc.titleTrinucleotide repeat expansion length as a predictor of the clinical progression of Fuchs' Endothelial Corneal Dystrophy
dc.contributor.authorSoh Y.Q.
dc.contributor.authorLim G.P.S.
dc.contributor.authorHtoon H.M.
dc.contributor.authorGong X.
dc.contributor.authorVinod Mootha V.
dc.contributor.authorVithana E.N.
dc.contributor.authorKocaba V.
dc.contributor.authorMehta J.S.
dc.date.accessioned2020-03-23T06:17:34Z
dc.date.available2020-03-23T06:17:34Z
dc.date.issued2019
dc.identifier.citationSoh Y.Q., Lim G.P.S., Htoon H.M., Gong X., Vinod Mootha V., Vithana E.N., Kocaba V., Mehta J.S. (2019). Trinucleotide repeat expansion length as a predictor of the clinical progression of Fuchs' Endothelial Corneal Dystrophy. PLoS ONE 14 (1) : e0210996. ScholarBank@NUS Repository. https://doi.org/10.1371/journal.pone.0210996
dc.identifier.issn19326203
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/165887
dc.description.abstractPurpose To determine if CTG18.1 TNR expansion length prognosticates the clinical progression of Fuchs' Endothelial Corneal Dystrophy (FECD). Methods This was a prospective cohort study. A total of 51 patients with newly diagnosed FECD were recruited and followed-up over a period of 12 years, from November 2004 to April 2016. Baseline clinical measurements included central corneal thickness (CCT), endothelial cell density (ECD) and CTG18.1 TNR expansion length from peripheral leukocytes, with yearly repeat measurements of CCT and ECD. A patient was defined to have experienced significant clinical progression and to have developed Threshold Disease if any of these criteria were fulfilled in either eye: a) CCT increased to >700?m, b) ECD decreased to <700 cells/ mm 2 , or c) underwent keratoplasty for treatment of FECD. Results Patients were categorized as having at least one allele whose maximum allele length was equal to or greater than 40 repeats (L40, n = 22, 43.1%), or having both alleles shorter than 40 repeats (L<40). Threshold Disease rates at the 5-year time point were 87.5% for the L40 group and 47.8% for the L<40 group (p = 0.012). This difference narrowed and was no longer statistically significant at the 8-years (92.9% vs 78.9%, p = 0.278) and 10-years (92.9% vs 84.2%, p = 0.426) time points. Conclusions L40 patients are at greater risk of FECD progression and development of Threshold Disease within the first 5 years following diagnosis. © 2019 Soh et al.
dc.publisherPublic Library of Science
dc.sourceUnpaywall 20200320
dc.subjectadult
dc.subjectallele
dc.subjectArticle
dc.subjectcell density
dc.subjectcentral corneal thickness
dc.subjectcohort analysis
dc.subjectcongenital cornea dystrophy
dc.subjectdisease course
dc.subjectdisease severity
dc.subjectendothelium cell
dc.subjectethnicity
dc.subjectfemale
dc.subjectfollow up
dc.subjecthuman
dc.subjectkeratoplasty
dc.subjectleukocyte count
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectprognosis
dc.subjectrisk assessment
dc.subjecttrinucleotide repeat
dc.typeArticle
dc.contributor.departmentDUKE-NUS MEDICAL SCHOOL
dc.description.doi10.1371/journal.pone.0210996
dc.description.sourcetitlePLoS ONE
dc.description.volume14
dc.description.issue1
dc.description.pagee0210996
Appears in Collections:Elements
Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1371_journal_pone_0210996.pdf1.67 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.